Results 81 to 90 of about 3,471 (204)

Vitamin D preparations: alfacalcidol (one-alpha) and others

, 1979
Since we last discussed vitamin D therapy1 the synthetic vitamin D analogue 1α-hydroxyvitamin D3 has become available as alfacalcidol (One-Alpha - Leo).

core   +1 more source

Effect of canagliflozin combined with alfacalcidol in the treatment of elderly type 2 diabetes mellitus with osteoporosis

Zhongguo linchuang yanjiu
Objective To investigate the clinical efficacy of canagliflozin combined with alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus（T2DM）and osteoporosis. Methods A randomized controlled trial design was adopted.
HUANG Yi*，JIANGXiong，PENG Jun，GUI Xiao，LIU Shuang，LI Peng，LI Yanling，JIANG Meiling
doaj   +1 more source

Die Wirkung von Etelcalcetid versus Alfacalcidol auf soluble Klotho in Hämodialysepatienten mit linksventrikulärer Hypertrophy

, 2020
In früheren Studien wurde festgestellt, dass soluble Klotho (sKl) ein Prädiktor für Nierenschädigungen und chronische Nierenerkrankungen (CKD) ist.
Steinringer, Stefan
core   +2 more sources

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol

, 2011
Background. Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D. In patients with chronic kidney disease, plasma FGF23 levels are markedly elevated by unknown mechanisms.
L. Brandi, Pedersen, S.M., Rasmussen, Knud, D. Hansen, Hansen, Ditte, L. M. Rasmussen, Brandi, L., Pedersen, Susanne M, Rasmussen, K., Brandi, Lisbet, S. M. Pedersen, K. Rasmussen, Hansen, D., Rasmussen, L.M., Rasmussen, Lars M   +14 more
core   +1 more source

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial [PDF]

, 2011
Alfacalcidol and paricalcitol are vitamin D analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia.
Madsen, Jens, Henning Danielsen, Peter Marckmann, Bacevicius, Egidijus, Ditte Hansen, Egidijus Bacevicius, Hansen, Ditte, Nielsen, Eva, Nielsen, Jørgen E., Peter Thye-Roenn, Jørgen E. Nielsen, Birgitte G. Tougaard, Tougaard, Birgitte G., Lauridsen, Thomas G., Thomas G. Lauridsen, Rasmussen, Knud, Thye-Roenn, Peter, Knud Rasmussen, Jens K. Madsen, Svend Kreiner, Marckmann, Peter, Meyer-Hofmann, Helmut, Kreiner, Svend, Brandi, Lisbet, Lauridsen, Thomas Guldager, Tougaard, Birgitte G, Helmut Meyer-Hofmann, Lisbet Brandi, Madsen, Jens Kristian, Madsen, Jens K., Nielsen, Jørgen Erik, Danielsen, Henning   +31 more
core   +1 more source

Vitamin D metabolism in diabetic nephropathy

Ожирение и метаболизм
Diabetic nephropathy (DN) is a specific kidney involvement in diabetes mellitus (DM), caused by hemodynamic and metabolic factors. In the kidneys takes place an important step in the metabolism of vitamin D — 1α-hydroxylation, which results in the ...
Z. V. Abilov, R. Kh. Salimkhanov, A. A. Povaliaeva, A. Yu. Zhukov, E. A. Pigarova, L. K. Dzeranova, L. Ya. Rozhinskaya   +6 more
doaj   +1 more source

Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease

Терапевтический архив, 2014
AIM: To evaluate the efficacy and safety of alfacalcidol and paracalcitol used to correct impaired phosphorus-calcium metabolism (PCM) in patients with predialysis chronic kidney disease (CKD)/MATERIAL AND METHODS: Examinations were made in 128 patients ...
L Iu Milovanova, I A Dobrosmyslov, Iu S Milovanov   +2 more
doaj  

[Alendronate more effective than alfacalcidol in the prevention of osteoporosis in patients with rheumatic disease who are starting glucocorticoid therapy] [PDF]

, 2007
Contains fulltext : 52836.pdf (Publisher’s version ) (Open Access)OBJECTIVE: To compare the effects of alendronate and alfacalcidol in the prevention ofglucocorticoid-related osteoporosis in patients with a rheumatic disease.
Laan, R.F.J.M., Geusens, P.P., Lems, W.F., Buskens, E., Bruyn, G.A.W., Huisman, A.M., Jacobs, J.W., Bijlsmat, J.W., Nijs, R.N. de, Laet, C.E. de, Algra, A., Dijkmans, B.A.C., Oostveen, J.C.   +12 more
core  

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial

, 2010
ObjectiveIn the 18 month "alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial (STOP-trial) patients with rheumatic diseases who started glucocorticoids were randomised to anti-osteoporosis therapy with either daily alendronate (10 ...
Jacobs, J. W. G., Hulsmans, H. M. J., Hoes, J. N., Bijlsma, Johannes W J, de Nijs, R. N. J. T. L., Lems, Willem F., Bruyn, G. A. W., Geusens, P. P. M. M.   +7 more
core  

Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol

, 2013
Currently beta-adrenergic receptor blockers are considered to be potential drugs under investigation for preventive or therapeutic effect in osteoporosis.
Bhat, MR, Khajuria, Deepak Kumar, Razdan, Rema, Mahapatra, Roy D   +3 more
core   +1 more source